Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q3 2018 Earnings Conference Call Transcript
Nov 07, 2018 • 04:30 pm ET
Good afternoon, and welcome to the Voyager Therapeutics Third Quarter 2018 Financial Results and Corporate Highlights Conference Call. (Operator Instructions) Please be advised that this call is being recorded at the company's request. At this time, I'd like to turn it over to Matt Osborne, Voyager's Vice President of Corporate Affairs, Communications and Investor Relations. Please proceed.
Thank you. Good afternoon, and welcome to the conference call. This afternoon, we issued a press release which outlines the recent corporate highlights and financial results for the third quarter of 2018 and provides financial guidance for 2018. We also issued a separate press release providing an update on the longer-term clinical results with VY-AADC for Parkinson's disease. These releases are available at voyagertherapeutics.com. Today on call, Andre Turenne, Voyager's President and CEO, will review our recent corporate and clinical program highlights; Dinah Sah, Voyager's Chief Scientific Officer, will review updates with our preclinical pipeline program; and Allison Dorval, Voyager's Chief Financial Officer, will review the financials. And then we will open up the call for your questions. (Forward-Looking Cautionary Statements) With that, I'll pass the call over to Andre.